Span Divergent Limited is an Indian strategic investment and management holding company specializing in the **Food, Agriculture, and Life Sciences** sectors. Since transitioning from its legacy IVD business in **2015**, the company has adopted a decentralized model, operating through specialized subsidiaries and LLPs. The company functions as the **Chief Operating Decision Maker (CODM)**, providing financial backing, technical expertise, and management consulting to its portfolio entities. --- ### **Core Business Verticals and Subsidiary Ecosystem** The company’s operations are categorized into three primary reportable segments: **Cashew Processing**, **Tissue Culture**, and **Trading**. | Subsidiary / Entity | Segment | Ownership / Status | Strategic Role & Recent Developments | |:---|:---|:---|:---| | **Dryfruit Factory LLP (DFFL)** | Food Processing | Material Subsidiary | Operates an **ISO 9001:2015** & **FSSC 22000** plant near Ahmedabad. Transitioned from a tolling model to direct **Raw Cashew Nut (RCN)** processing in **Oct-24**. | | **Biospan Contamination Control Solutions (BCCS)** | Life Sciences | **67%** JV with **Micronclean UK** | Supplies cleanroom consumables to Pharma/Biotech. Currently in a turnaround phase to address negative net worth. | | **Aranya Agri Biotech LLP (AABL)** | Agriculture | Re-activated | Specializes in **Tissue Culture** (Banana/Pomegranate). Operations were suspended in **Sept-2023** but approved for revival in **Nov-2025**. | | **Biospan Scientific LLP (BSLLP)** | Life Sciences | Trading | Distributes niche products for Biotech manufacturing. Reported **INR 1.82 crore** revenue in FY25. | | **Span Diagnostics LLP** | Inoperative | Exited | **99%** stake sold in **Nov-2025** for **INR 99,000** to eliminate an infructuous entity. | | **Desai Farmharvest LLP** | Inoperative | Dissolved | Voluntarily struck off effective **May 13, 2025**. | --- ### **Strategic Pivot: Cashew Processing and Operational Restructuring** A central pillar of the current strategy is the revitalization of **Dryfruit Factory LLP (DFFL)**. The company has shifted away from long-term tolling contracts to a self-managed model of purchasing and processing **Raw Cashew Nuts (RCN)**. * **Inventory Strategy:** Management is focusing on the **West Africa crop window** to secure **2-3 months** of RCN inventory upfront, ensuring cost-competitive procurement. * **Facility Maintenance:** The Ahmedabad plant underwent significant maintenance and resumed operations on **June 16, 2025**. * **Capital Allocation:** Recent fundraising is specifically earmarked for labor mobilization, plant commissioning, and selective equipment refurbishment to improve kernel yields. --- ### **Advanced Agricultural Technology: Tissue Culture Operations** Through **Aranya Agri Biotech LLP (AABL)**, the company utilizes laboratory-controlled propagation to produce high-quality, disease-free plants. * **Product Portfolio:** Primary focus on **Banana** and **Pomegranate** tissue culture plants. * **Methodology:** A rigorous cycle exceeding **12 months**, involving **Initiation** (aseptic cultures), **Multiplication**, and a two-stage **Hardening** process (Primary and Secondary) to ensure field readiness. * **Valuation (Ind AS 41):** Biological assets are valued at **Fair Value less cost to sell**, derived from projected cash flows during the growth cycle using a discounting factor. * **Revival Plan:** Despite being classified as "Held for Sale" in 2023 due to **INR 15.13 crore** in accumulated losses, the Board reclassified these assets back to **Property, Plant, and Equipment (PPE)** in **Nov-2025** to pursue new market opportunities. --- ### **Capital Structure and Recent Fundraising** The company has recently strengthened its balance sheet to fund its operational turnaround. * **Preferential Allotment (March 2026):** Issued **1,801,481 equity shares** to a non-promoter investor (**Mr. Neev Nirav Jogani**) at **INR 32.16** per share (Premium: **INR 22.16**). * **Proceeds:** Raised approximately **INR 5.79 Crores**, increasing the post-issue paid-up capital to **INR 7.26 Crores** (**7,263,228 shares**). * **Promoter Holding:** Major stakeholders include **Dr. Pradipkumar Keshavlal Desai (42.77%)**, **Viral Pradipkumar Desai (12.60%)**, and **Bharti Patel (10.53%)**. * **Leadership Transition:** **Dr. Pradipkumar Keshavlal Desai** moved to the role of **Chairman Emeritus** in **Nov-2025**, providing technical advisory, while **Mr. Rajendra Chokhawala** serves as Independent Chairman. --- ### **Financial Performance and Asset Management** The company is currently navigating a period of revenue contraction and resource conservation. | Consolidated Metric (INR Lacs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Consolidated Sales** | **896.01** | **1,233.26** | **1,252.48** | | **Net Profit (Attributable)** | **(91.73)** | **97.55** | **(505.46)** | | **Gearing Ratio** | -- | -- | **12.42%** | * **Dividend Policy:** No dividends were recommended for **FY 2024-25** as the company prioritizes cash conservation and the absorption of accumulated losses. * **Asset Monetization:** The company successfully sold immovable property in **Citylight, Surat (March 2024)** and continues to evaluate the sale of non-core assets to unlock liquidity. * **Management Fees:** The parent company generates revenue by charging subsidiaries management fees based on their turnover and interest on fluctuating capital. --- ### **Risk Profile and Mitigation Framework** The company operates a formal risk management framework overseen by the **Audit Committee**, focusing on the following areas: * **Subsidiary Financial Stress:** * **BCCS** has a negative net worth with liabilities exceeding assets by **INR 6.81 Crores**. Management expects a turnaround by **2025** through new product licenses. * **BSLLP** underwent a **INR 1.83 Crore** impairment in FY19; revival efforts via new business tie-ups are ongoing. * **Contingent Liabilities:** The company has extended significant corporate guarantees to support subsidiary credit lines, including **INR 5.25 crore** for **BCCS** and **INR 3.5 crore** for **DFFL**. Total guarantees reached **INR 460.34 Crores** by March 2025. * **Foreign Exchange Risk:** **BCCS** and **BSLLP** are exposed to **GBP/INR** fluctuations due to the import of life science consumables. * **Legal and Tax Risks:** Pending income tax disputes for **A.Y. 2012-13** and **2013-14** total **INR 1.51 Crores**. Additionally, a **INR 8.00 Crore** lawsuit from a former subsidiary employee remains a contingent liability. * **Market Sensitivities:** Borrowings are primarily at **floating interest rates**, making the company sensitive to interest rate hikes. Actuarial valuations for employee benefits are also sensitive to discount rate changes (a **1% decrease** in discount rate impacts obligations by **1.28**).